<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04437368</url>
  </required_header>
  <id_info>
    <org_study_id>GT005-02</org_study_id>
    <nct_id>NCT04437368</nct_id>
  </id_info>
  <brief_title>EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005</brief_title>
  <acronym>EXPLORE</acronym>
  <official_title>EXPLORE: A Phase II, Outcomes Assessor-masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyroscope Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyroscope Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and efficacy of two doses of&#xD;
      GT005 administered as a single subretinal injection in subjects with geographic atrophy&#xD;
      secondary to age-related macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, outcomes assessor-masked, multicentre, randomised study to evaluate the&#xD;
      safety and efficacy of two doses of GT005 administered as a single subretinal injection in&#xD;
      subjects with GA secondary to AMD.&#xD;
&#xD;
      The trial includes a screening period of up to 8 weeks followed by a 96-week study period.&#xD;
&#xD;
      Subjects will be randomised to one of two groups: GT005 or the untreated control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Phase 2, outcomes assessor-masked multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The overall objectives of the study are to evaluate the safety and efficacy (anatomical and functional visual outcomes) of two doses of GT005 in genetically defined subjects with GA due to AMD.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of geographic atrophy</measure>
    <time_frame>48 weeks</time_frame>
    <description>The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of geographic atrophy</measure>
    <time_frame>72 weeks and 96 weeks</time_frame>
    <description>The change from baseline to Week 72 and Week 96 in GA area as measured by fundus autofluorescence (FAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and tolerability of GT005</measure>
    <time_frame>96 weeks</time_frame>
    <description>Frequency of treatment emergent adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on retinal anatomical measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in retinal microstructures on optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on retinal anatomical measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in presence of area of nascent GA on OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on retinal anatomical measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in GA morphology on multimodal imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on functional measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Macular sensitivity as assessed by mesopic Microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on functional measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in BCVA Score via the early treatment for diabetic retinopathy (ETDRS) chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on functional measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in low luminance difference (LLD) via the ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on visual function</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in reading performance as assessed by Minnesota low-vision reading test (MNRead) Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on visual function</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in functional reading independence (FRI) index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on patient-reported outcomes</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in quality of life measured on the Visual Functioning Questionnaire-25 (VFQ-25)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>GT005 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Approximately 25 subjects are planned, with subjects randomised to untreated control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GT005; Low Dose</intervention_name>
    <description>The study will test two doses of GT005: Low Dose and High Dose.</description>
    <arm_group_label>GT005 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GT005; High Dose</intervention_name>
    <description>The study will test two doses of GT005: Low Dose and High Dose.</description>
    <arm_group_label>GT005 High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to give written informed consent&#xD;
&#xD;
          2. Age â‰¥55 years&#xD;
&#xD;
          3. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by&#xD;
             the Investigator, and a diagnosis of AMD in the contralateral eye&#xD;
&#xD;
          4. GA lesion(s) within an acceptable size on FAF, in the study eye&#xD;
&#xD;
          5. The GA lesion(s) in the study eye must reside completely within the FAF image&#xD;
&#xD;
          6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye&#xD;
&#xD;
          7. Have a BCVA of 24 letters (6/95 and 20/320 Snellen acuity equivalent) or better, using&#xD;
             ETDRS charts, in the study eye&#xD;
&#xD;
          8. Have a rare genetic variant of the CFI gene, defined as a minor allele frequency of&#xD;
             &lt;1%&#xD;
&#xD;
          9. Able to attend all study visits and complete the study procedures&#xD;
&#xD;
         10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks&#xD;
             prior to randomisation (not required for women who are postmenopausal or surgically&#xD;
             sterilised)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history, or evidence, of CNV in the study eye&#xD;
&#xD;
          2. Presence of moderate/severe or worse non-proliferative diabetic retinopathy in the&#xD;
             study eye&#xD;
&#xD;
          3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the&#xD;
             study eye&#xD;
&#xD;
          4. History of intraocular surgery in the study eye within 12 weeks prior to Screening.&#xD;
&#xD;
          5. Have clinically significant cataract that may require surgery during the study period&#xD;
             in the study eye.&#xD;
&#xD;
          6. Presence of moderate to severe glaucomatous optic neuropathy in the study eye,&#xD;
             uncontrolled intraocular pressure (IOP) despite the use of more than two topical&#xD;
             agents, or a history of glaucoma-filtering or valve surgery&#xD;
&#xD;
          7. Axial myopia of greater than -8 diopters in the study eye&#xD;
&#xD;
          8. Have any other significant ocular or non-ocular medical or psychiatric condition&#xD;
             which, in the opinion of the Investigator, may either put the subject at risk or may&#xD;
             influence the results of the study&#xD;
&#xD;
          9. Have a contraindication to the specified protocol corticosteroid regimen&#xD;
&#xD;
         10. Have received any investigational product for the treatment of GA within the past 6&#xD;
             months, or 5 half-lives (whichever is longer) other than nutritional supplements such&#xD;
             as the age-related eye disease study (AREDS) formula&#xD;
&#xD;
         11. Have received a gene or cell therapy at any time&#xD;
&#xD;
         12. Are unwilling to use two forms of contraception (one of which being a barrier method)&#xD;
             for 90 days post-dosing, if relevant&#xD;
&#xD;
         13. Active malignancy within the past 12 months, except for: appropriately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with&#xD;
             a stable prostate-specific antigen (PSA) &gt;12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gyroscope Therapeutics</last_name>
    <phone>+441438532142</phone>
    <email>clinicaltrials@gyroscopetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute Northside</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston (OCB)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harkness Eye Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western New York</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charles Retina Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Melbourne - The Centre for Eye Research Australia (CERA)</name>
      <address>
        <city>Melbourne E.</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Paradis Monticelli</name>
      <address>
        <city>Marseille</city>
        <state>Alpes-Cote d'Azur</state>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU HÃ´pital F. Mitterrand</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne-Franche-ComtÃ©</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - HÃ´tel-Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus LÃ¼beck</name>
      <address>
        <city>LÃ¼beck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Makula-Netzhaut-Zentrum</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40549</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum TÃ¼bingen</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya</name>
      <address>
        <city>Sant Cugat Del VallÃ¨s</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VISSUM Mirasierra</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad De Madrid</state>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra - Pamplona</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geographic atrophy</keyword>
  <keyword>Retinal disease</keyword>
  <keyword>Eye disease</keyword>
  <keyword>Retinal degeneration</keyword>
  <keyword>Macular atrophy</keyword>
  <keyword>Dry age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

